Hormonal
Peripheral administration of PYY 3-36 significantly inhibits food intake in humans by acting on hypothalamic Y2 receptors to suppress orexigenic NPY neurons.
Your gut naturally releases a hormone called PYY 3-36 after eating to tell your brain you are full. Research shows that maintaining or enhancing this signal can significantly reduce how much you eat. While current treatments focus on other pathways, understanding this natural mechanism highlights the importance of foods that stimulate gut hormone release for satiety.
Peripheral administration of PYY 3-36 leads to a marked inhibition in food intake. In human volunteers, an exogenous infusion accurately mimicking postprandial PYY 3-36 concentrations reduced food intake by 30% when compared with saline control... PYY3-36 has a high affinity for the Y2 receptor... its action is via the hypothalamus... circulating PYY3-36 inhibits appetite by acting directly on the arcuate nucleus to inhibit orexigenic NPY neurones.
Why this rating
Based on a cited double-blinded cross-over study in human volunteers showing a 30% reduction.
Source
Appetite regulation: from the gut to the hypothalamus
Nicola M. Neary et al. · Clinical Endocrinology · 2003
DOI 10.1046/j.1365-2265.2003.01839.x
More from this paper
- Gastric bypass surgery reduces appetite and promotes long-term weight loss primarily through hormonal changes, specifically decreased ghrelin and increased PYY, rather than solely mechanical restriction.Good
- Leptin treatment is effective for weight loss only in individuals with congenital leptin deficiency, but offers limited benefit for the vast majority of obese people who have high circulating leptin.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →